AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16858241 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led education programme, facilitated telephone communication and follow-up visits with an internist at 15 days, 1 and 6 months
Number of subjects: 200
Study 16858241 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (follow-up by their primary care physician)
Number of subjects: 200
Study 12895265 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN alpha)-2b + ribavirin (1-1.2 g/day) for 1 year
Number of subjects: 191
Study 12895265 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha (IFN alpha)-2b for 1 year
Number of subjects: 191
Study 12895265 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN alpha)-2b + ribavirin (1-1.2 g/day) at the end of treatment
Number of subjects: 191
Study 12895265 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha (IFN alpha)-2b at the end of treatment
Number of subjects: 191
Study 10646156 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 0.5% drops for anesthesia
Number of subjects: 100
Study 10646156 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual lorazepam 1 mg before surgery
Number of subjects: 100
Study 10646156 — intervention group
Group type: COMPARATOR
Intervention: No sublingual lorazepam
Number of subjects: 100
Study 9015118 — intervention group
Group type: EXPERIMENTAL
Intervention: Rota colostrum (20 ml for 2 weeks)
Number of subjects: 20
Study 9015118 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study 9015118 — intervention group
Group type: EXPERIMENTAL
Intervention: Rota colostrum (every other day)
Number of subjects: 20
Study 1825857 — intervention group
Group type: EXPERIMENTAL
Intervention: Atriopeptin III (AP‐3) 0.1 micrograms/kg/min
Number of subjects: 38
Study 1825857 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 38
Study 6626699 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone capsule (1 g)
Number of subjects: 4
Study 6626699 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone suspension (1 g)
Number of subjects: 4
Study 6626699 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of methylprednisolone
Number of subjects: 4
Study 6626699 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pulse therapy
Number of subjects: 4
Study 29516771 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualised ADL retraining following errorless and procedural learning principles during PTA
Number of subjects: 49
Study 29516771 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualised ADL retraining
Number of subjects: 49
Study 29248390 — intervention group
Group type: EXPERIMENTAL
Intervention: School-located influenza vaccination (SLIV) in suburban schools
Number of subjects: 17650
Study 29248390 — intervention group
Group type: EXPERIMENTAL
Intervention: School-located influenza vaccination (SLIV) in urban schools
Number of subjects: 17650
Study 29248390 — intervention group
Group type: EXPERIMENTAL
Intervention: School-located influenza vaccination (SLIV) in suburban settings
Number of subjects: 17650
Study 29248390 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 17650
Study 26919191 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted ventral mesh rectopexy (RVMR)
Number of subjects: 30
Study 26919191 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ventral mesh rectopexy (LVMR)
Number of subjects: 30
Study 25065424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 8 mg·kg(‐1)
Number of subjects: 112
Study 25065424 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 3 μg·kg(‐1)
Number of subjects: 112
Study 25065424 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 4 μg·kg(‐1)
Number of subjects: 112
Study 25065424 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 5 μg·kg(‐1)
Number of subjects: 112
Study 22747316 — intervention group
Group type: EXPERIMENTAL
Intervention: $5 incentive for each name and valid address or phone number
Number of subjects: 2968
Study 22747316 — intervention group
Group type: EXPERIMENTAL
Intervention: $20 incentive for each completed mammogram
Number of subjects: 2968
Study 22747316 — intervention group
Group type: COMPARATOR
Intervention: No financial incentive for nomination
Number of subjects: 2968
Study 20923996 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg once daily or 30 mg twice daily)
Number of subjects: 18405
Study 17919551 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d for 3 weeks before surgery
Number of subjects: 40
Study 17919551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15565083 — intervention group
Group type: EXPERIMENTAL
Intervention: Food For Heart Program (dietary counseling visits)
Number of subjects: 175
Study 15565083 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 175
Study 11226788 — intervention group
Group type: EXPERIMENTAL
Intervention: Foldable hydrophobic acrylic IOL (AcrySof, Alcon)
Number of subjects: 62
Study 11226788 — intervention group
Group type: COMPARATOR
Intervention: Heparin-surface-modified (HSM) PMMA IOL (811C, Pharmacia)
Number of subjects: 62
Study 10806662 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (oral administration for 8-12 weeks)
Number of subjects: 23
Study 8282323 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.4 mg/d) treatment with ad libitum diet
Number of subjects: 11
Study 8282323 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.4 mg/d) with a 150 mmol/24 h sodium diet
Number of subjects: 11
Study 8282323 — intervention group
Group type: COMPARATOR
Intervention: Placebo with a 150 mmol/24 h sodium diet
Number of subjects: 11
Study 2917417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravelar veloplasty (IVV)
Number of subjects: 51
Study 2917417 — intervention group
Group type: COMPARATOR
Intervention: Control procedure (non-IVV)
Number of subjects: 51
Study 179286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid analogue (antilipolytic agent)
Number of subjects: 21
Study 179286 — intervention group
Group type: COMPARATOR
Intervention: Isoprenaline infusion (control for dogs)
Number of subjects: 21
Study 179286 — intervention group
Group type: COMPARATOR
Intervention: Patients with acute myocardial infarction
Number of subjects: 21
Study 30268158 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electrostimulation (ES) administered via CarebandR device on unilateral PC6 acupoint.
Number of subjects: 80
Study 30268158 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine or pregabalin prescribed to all participants.
Number of subjects: 80
Study 27208863 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl pectin nasal spray (FPNS)
Number of subjects: 167
Study 27208863 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine (OM)
Number of subjects: 167
Study 24280031 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep rTMS to bilateral dorsomedial prefrontal cortex (5 Hz, 10‐s train duration, 20‐s inter‐train interval) for 15 min (1500 pulses per session)
Number of subjects: 28
Study 24280031 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep rTMS to bilateral dorsomedial prefrontal cortex
Number of subjects: 28
Study 24280031 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 28
Study 22951287 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-102 (35 mg/m² orally twice a day in a 28-day cycle)
Number of subjects: 169
Study 22951287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 21083880 — intervention group
Group type: EXPERIMENTAL
Intervention: GFU (Glaucoma Follow-up Unit)
Number of subjects: 815
Study 21083880 — intervention group
Group type: COMPARATOR
Intervention: Glaucoma specialist group
Number of subjects: 815
Study 18687253 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI + efavirenz
Number of subjects: 82
Study 18687253 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI + lopinavir/ritonavir
Number of subjects: 82
Study 18687253 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz + lopinavir/ritonavir
Number of subjects: 82
Study 15903373 — intervention group
Group type: EXPERIMENTAL
Intervention: Lode Excalibur Sport Ergometer
Number of subjects: 26
Study 15903373 — intervention group
Group type: COMPARATOR
Intervention: Computrainer
Number of subjects: 26
Study 12877794 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg
Number of subjects: 197
Study 12877794 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 197
Study 11009140 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg rifampicin
Number of subjects: 126
Study 11009140 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg rifampicin
Number of subjects: 126
Study 11009140 — intervention group
Group type: COMPARATOR
Intervention: 200 mg doxycycline
Number of subjects: 126
Study 11009140 — intervention group
Group type: COMPARATOR
Intervention: Combined regimen (doxycycline with rifampicin)
Number of subjects: 126
Study 8866630 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (1% solution) microinjection
Number of subjects: 0
Study 8866630 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline microinjection
Number of subjects: 0
Study 8866630 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (1% solution) combined with oral intake of 20 mg cetirizine
Number of subjects: 0
Study 1324483 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan fibers (DICOMAN 5:2‐3 gr/die), 2-3 caps twice a day
Number of subjects: 23
Study 1324483 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 obese children, aged 5‐18 years)
Number of subjects: 23
Study 6501718 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 2789
Study 31895174 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual morphine (10 mg)
Number of subjects: 10
Study 31895174 — intervention group
Group type: COMPARATOR
Intervention: Swallowed morphine (10 mg)
Number of subjects: 10
Study 30999565 — intervention group
Group type: EXPERIMENTAL
Intervention: Raman spectroscopy of blood in microvessels
Number of subjects: 12
Study 30353267 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body cryotherapy (WBC) using Cryosense TCT cabin
Number of subjects: 60
Study 27888177 — intervention group
Group type: EXPERIMENTAL
Intervention: Novartis Access NCD medicines provided through public and private non-profit health facilities.
Number of subjects: 1184
Study 27888177 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to Novartis Access NCD medicines).
Number of subjects: 1184
Study 25292399 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment-based abstinence reinforcement
Number of subjects: 33
Study 22344549 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of ondansetron 8 mg orodispersible tablet
Number of subjects: 22
Study 22344549 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of ondansetron 8 mg orodispersible tablet
Number of subjects: 22
Study 20488402 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic-coated introducer sheath
Number of subjects: 790
Study 20488402 — intervention group
Group type: COMPARATOR
Intervention: Uncoated introducer sheath
Number of subjects: 790
Study 20488402 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sheath types
Number of subjects: 790
Study 17682078 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one peer support (treatment group, n = 37)
Number of subjects: 72
Study 17682078 — intervention group
Group type: COMPARATOR
Intervention: Usual health care (control group, n = 35)
Number of subjects: 72
Study 16223581 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postoperative irradiation
Number of subjects: 972
Study 16223581 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see (W and S)
Number of subjects: 972
Study 12137870 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection and analysis of blood, leukocytic DNA, semen, and testicular biopsy
Number of subjects: 132
Study 12137870 — intervention group
Group type: COMPARATOR
Intervention: Control group of males with proven fertility
Number of subjects: 132
Study 10453931 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g oral ganciclovir daily for 8 weeks
Number of subjects: 15
Study 10453931 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g oral ganciclovir daily for 8 weeks
Number of subjects: 15
Study 7605354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 625
Study 7605354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day with APOE*2 allele
Number of subjects: 625
Study 7605354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day with APOE*3 allele
Number of subjects: 625
Study 7605354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day with APOE*4 allele
Number of subjects: 625
Study 7605354 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis including APOE*2 allele
Number of subjects: 625
Study 2447151 — intervention group
Group type: EXPERIMENTAL
Intervention: citalopram
Number of subjects: 29
Study 2447151 — intervention group
Group type: EXPERIMENTAL
Intervention: maprotiline
Number of subjects: 29
Study 2447151 — intervention group
Group type: COMPARATOR
Intervention: citalopram and maprotiline
Number of subjects: 29
Study 2447151 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone Suppression Test (DST)
Number of subjects: 29
Study 2447151 — intervention group
Group type: COMPARATOR
Intervention: HVA and MHPG concentrations in lumbar-CSF
Number of subjects: 29
Study 29543138 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (T)
Number of subjects: 60
Study 29543138 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-reduced diet (D)
Number of subjects: 60
Study 29543138 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and energy increased diet (T-iD)
Number of subjects: 60
Study 29543138 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 60
Study 26752621 — intervention group
Group type: EXPERIMENTAL
Intervention: LY544344 (mGluR2/3 agonist)
Number of subjects: 8
Study 26752621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 25185277 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal irrigation (group B)
Number of subjects: 61
Study 25185277 — intervention group
Group type: COMPARATOR
Intervention: Nasal steroid spray (group A)
Number of subjects: 61
Study 25185277 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal irrigation combined with nasal steroid (group C)
Number of subjects: 61
Study 22790213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa extract (CR)
Number of subjects: 0
Study 22790213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17928819 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dosing of enoxaparin
Number of subjects: 0
Study 17928819 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosing of enoxaparin
Number of subjects: 0
Study 19242074 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal sphincterotomy
Number of subjects: 108
Study 19242074 — intervention group
Group type: COMPARATOR
Intervention: Topical 2% Diltiazem ointment
Number of subjects: 108
Study 16356429 — intervention group
Group type: EXPERIMENTAL
Intervention: Overtreatment of thyroid hormone replacement
Number of subjects: 45
Study 16356429 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal initial treatment of thyroid hormone replacement
Number of subjects: 45
Study 16356429 — intervention group
Group type: COMPARATOR
Intervention: Initial treatment factors (free thyroxine and TSH concentrations)
Number of subjects: 45
Study 11977339 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 378 mg/day
Number of subjects: 48
Study 11977339 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB) 43 mg/g
Number of subjects: 48
Study 9231868 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment for chronic low back pain
Number of subjects: 17
Study 9231868 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (Control)
Number of subjects: 17
Study 8254858 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPS II score
Number of subjects: 13152
Study 3301444 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 11
Study 3301444 — intervention group
Group type: COMPARATOR
Intervention: Optimized conventional insulin therapy
Number of subjects: 11
Study 11571605 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT supplementation during VLCD
Number of subjects: 0
Study 11571605 — intervention group
Group type: COMPARATOR
Intervention: LCT supplementation during VLCD
Number of subjects: 0
Study 11571605 — intervention group
Group type: COMPARATOR
Intervention: Low-fat high-carbohydrate regimen
Number of subjects: 0
Study 30921815 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary blinks
Number of subjects: 0
Study 30921815 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexive blinks (elicited by air puffs)
Number of subjects: 0
Study 30921815 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal displacements (horizontal direction)
Number of subjects: 0
Study 30921815 — intervention group
Group type: EXPERIMENTAL
Intervention: Downward displacements (vertical direction)
Number of subjects: 0
Study 30598705 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant force EMGBFB tibialis anterior exercise
Number of subjects: 33
Study 30598705 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable force EMGBFB tibialis anterior exercise
Number of subjects: 33
Study 30598705 — intervention group
Group type: COMPARATOR
Intervention: Upper extremity exercise without EMGBFB (control)
Number of subjects: 33
Study 27789674 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal vitamin A supplementation (50,000 IU)
Number of subjects: 31999
Study 27789674 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal vitamin A supplementation (50,000 IU) among infants born to women who received a mega-dose of vitamin A postpartum
Number of subjects: 31999
Study 27789674 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal vitamin A supplementation (50,000 IU) among infants born to women who did not receive a mega-dose of vitamin A postpartum
Number of subjects: 31999
Study 25394474 — intervention group
Group type: COMPARATOR
Intervention: Tongue scraper
Number of subjects: 60
Study 25394474 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy applied to the posterior two‐thirds of the dorsum of the tongue
Number of subjects: 60
Study 25394474 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (tongue scraper and photodynamic therapy)
Number of subjects: 60
Study 22814775 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 334
Study 22814775 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 334
Study 22814775 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafts (CABG)
Number of subjects: 334
Study 20153460 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential Interpersonal Treatment (RIPT)
Number of subjects: 80
Study 20153460 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential Cognitive Treatment (RCT)
Number of subjects: 80
Study 20153460 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 80
Study 18179132 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine‐vinorelbine‐cisplatin (GVP) regimen
Number of subjects: 1
Study 15909190 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 20
Study 15909190 — intervention group
Group type: COMPARATOR
Intervention: Saline infusions (Control)
Number of subjects: 20
Study 12011543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral telithromycin 800 mg once daily for 5 days (followed by placebo for 5 days), n = 170
Number of subjects: 341
Study 12011543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral telithromycin 800 mg once daily for 10 days, n = 171
Number of subjects: 341
Study 12011543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral telithromycin 800 mg once daily for 5 days
Number of subjects: 341
Study 12011543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral telithromycin 800 mg once daily for 10 days
Number of subjects: 341
Study 9614594 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin (average daily dose: 169.4 ± 41.6 mg)
Number of subjects: 36
Study 9614594 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (average daily dose: 36.8 ± 18 mg)
Number of subjects: 36
Study 8593195 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical formulations (including a new stabilized stannous fluoride dentifrice)
Number of subjects: 0
Study 8593195 — intervention group
Group type: COMPARATOR
Intervention: Non-treated plaque samples
Number of subjects: 0
Study 2508382 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (2,000 kcal/12.4 g N)
Number of subjects: 22
Study 2508382 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition (1,940 kcal/12.4 g N)
Number of subjects: 22
Study 4549499 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG strain (specific strain not mentioned)
Number of subjects: 0
Study 4549499 — intervention group
Group type: COMPARATOR
Intervention: Other BCG strains
Number of subjects: 0
Study 31583813 — intervention group
Group type: EXPERIMENTAL
Intervention: Family constellation seminars (FCS)
Number of subjects: 31
Study 31583813 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 31
Study 28827229 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS + sensorimotor retraining
Number of subjects: 80
Study 28827229 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS + sensorimotor retraining
Number of subjects: 80
Study 26341847 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard alcohol brief intervention with personalized alcohol response feedback (BI-ARF)
Number of subjects: 33
Study 26341847 — intervention group
Group type: COMPARATOR
Intervention: Standard alcohol brief intervention (BI-S)
Number of subjects: 33